Response Prediction for Anti-angiogenic Treatment in Recurrent Glioblastoma

CompletedOBSERVATIONAL
Enrollment

15

Participants

Timeline

Start Date

February 6, 2020

Primary Completion Date

August 31, 2021

Study Completion Date

November 1, 2022

Conditions
Adult GlioblastomaMagnetic Resonance ImagingBevacizimab
Interventions
DIAGNOSTIC_TEST

3-Tesla conventional magnetic resonance imaging

T1-weighted, T2-weighted, fluid-attenuated inversion recovery, and contrast-enhanced T1-weighted imaging

DIAGNOSTIC_TEST

Advanced imaging without contrast use

Diffusion-weighted imaging, amide proton transfer-weighted imaging, electrical properties tomography, and 2hG-magnetic resonance spectroscopy

DIAGNOSTIC_TEST

Dynamic susceptibility contrast-weighted imaging

Cerebral blood volume and vessel architectural imaging parameters

Trial Locations (1)

Unknown

Asan Medical Center, Seoul

All Listed Sponsors
lead

Ho Sung Kim

OTHER

NCT04143425 - Response Prediction for Anti-angiogenic Treatment in Recurrent Glioblastoma | Biotech Hunter | Biotech Hunter